Vaxcyte (PCVX) Competitors $85.30 -2.53 (-2.88%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PCVX vs. ARGX, BNTX, TEVA, BGNE, GMAB, VTRS, ITCI, MRNA, SMMT, and RDYShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include argenx (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. argenx BioNTech Teva Pharmaceutical Industries BeiGene Genmab A/S Viatris Intra-Cellular Therapies Moderna Summit Therapeutics Dr. Reddy's Laboratories Vaxcyte (NASDAQ:PCVX) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Which has more volatility and risk, PCVX or ARGX? Vaxcyte has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Is PCVX or ARGX more profitable? Vaxcyte has a net margin of 0.00% compared to argenx's net margin of -2.11%. argenx's return on equity of -1.45% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% argenx -2.11%-1.45%-1.29% Which has higher valuation and earnings, PCVX or ARGX? argenx has higher revenue and earnings than Vaxcyte. argenx is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-18.54argenx$1.27B30.48-$295.05M-$0.88-727.86 Do institutionals and insiders hold more shares of PCVX or ARGX? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 2.4% of argenx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer PCVX or ARGX? Vaxcyte currently has a consensus target price of $145.71, indicating a potential upside of 70.83%. argenx has a consensus target price of $658.39, indicating a potential upside of 2.79%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities analysts clearly believe Vaxcyte is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00argenx 1 Sell rating(s) 2 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the MarketBeat Community favor PCVX or ARGX? argenx received 602 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.00% of users gave Vaxcyte an outperform vote while only 67.19% of users gave argenx an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4575.00% Underperform Votes1525.00% argenxOutperform Votes64767.19% Underperform Votes31632.81% Does the media refer more to PCVX or ARGX? In the previous week, argenx had 22 more articles in the media than Vaxcyte. MarketBeat recorded 34 mentions for argenx and 12 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.70 beat argenx's score of 0.44 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenx 8 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVaxcyte and argenx tied by winning 9 of the 18 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.63B$2.96B$5.21B$9.14BDividend YieldN/A1.91%5.13%4.02%P/E Ratio-18.5445.5689.3417.36Price / SalesN/A275.871,240.0477.11Price / CashN/A192.9043.7535.97Price / Book6.543.965.314.79Net Income-$402.27M-$41.02M$122.54M$225.00M7 Day Performance5.09%0.19%0.59%2.62%1 Month Performance-1.42%-1.72%2.55%3.81%1 Year Performance40.83%-2.23%25.29%20.10% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte2.2146 of 5 stars$85.30-2.9%$145.71+70.8%+40.8%$10.63BN/A-18.54160Insider TradeARGXargenx2.3543 of 5 stars$665.99+1.5%$645.61-3.1%+74.6%$40.20B$1.86B-756.81650Analyst DowngradeAnalyst RevisionBNTXBioNTech2.8935 of 5 stars$112.94-8.1%$142.72+26.4%+14.0%$27.08B$3.04B-53.786,133Short Interest ↑Gap DownTEVATeva Pharmaceutical Industries1.78 of 5 stars$20.24-3.3%$20.88+3.1%+96.5%$22.93B$16.77B-23.8137,851Analyst ForecastBGNEBeiGene2.4103 of 5 starsN/A$253.69+∞N/A$18.03B$3.32B-22.4210,600Analyst ForecastPositive NewsGMABGenmab A/S4.4584 of 5 stars$21.71-2.0%$45.20+108.2%-28.1%$14.37B$19.84B21.082,204VTRSViatris2.2466 of 5 stars$11.72+0.4%$13.67+16.6%-0.9%$13.99B$15.05B-15.8437,000ITCIIntra-Cellular Therapies3.816 of 5 stars$127.26+34.1%$97.23-23.6%+92.8%$13.49B$612.78M-146.27560High Trading VolumeMRNAModerna4.7254 of 5 stars$34.88-17.4%$78.83+126.0%-65.8%$13.42B$5.06B-5.995,600Analyst RevisionHigh Trading VolumeSMMTSummit Therapeutics3.0612 of 5 stars$18.20+2.0%$33.57+84.5%+427.1%$13.42B$700,000.00-65.00105RDYDr. Reddy's Laboratories2.2931 of 5 stars$15.31-0.7%$17.00+11.0%+9.8%$12.78B$3.35B24.4627,048News Coverage Related Companies and Tools Related Companies argenx Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Genmab A/S Competitors Viatris Competitors Intra-Cellular Therapies Competitors Moderna Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCVX) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
